



Scandinavian ChemoTech Hosts Successful TSE Best Practice Sharing Session with Dr. Brendan Boostrom

Scandinavian ChemoTech today announced the successful completion of an international best practice exchange on its Tumor Specific Electroporation (TSE) technology on September 15th, 2025, featuring **Dr. Brendan Boostrom, DVM, MS, DACVIM (Oncology)** from Northern Virginia. Veterinary oncologists from one of the largest Veterinary Accounts in Europe took part to review clinical outcomes, share insights, and discuss protocols for treating companion animals with advanced oncology needs.

Sharing Clinical Experience Across Borders

During the session, Dr. Boostrom provided a comprehensive overview of his experience using vetIQure™ TSE with more than 250 treatments over the past three years. He presented a series of successfully treated cases in both dogs and cats, highlighting TSE's ability to achieve local tumor control while reducing side effects, damage to healthy tissue and improving quality of life.

"TSE has become a reliable treatment option for our patients, expanding our spectrum of care and proving more affordable than radiation or specialized surgery. We have now treated a diverse range of tumor types with encouraging results. By combining this highly targeted treatment with chemotherapy or immunotherapy, we have been able to achieve meaningful outcomes for our patients, often in cases where conventional options were limited. Through sharing our experiences with our European colleagues, we gained valuable insights and opportunities for collaboration.", said Dr. Brendan Boostrom, boarded veterinary oncologist treating dogs, cats and exotic pets in Northern Virginia.

Engaging Dialogue with European Colleagues

The European participants—representing leading veterinary oncology centers in Sweden, Switzerland, and Germany—engaged actively with Dr. Boostrom's case reviews and shared their own insights from using TSE in European clinics. The collaborative dialogue underscored the importance of international knowledge exchange to refine protocols and optimize patient outcomes.

Nanna Åkerlund, DVM, Specialist in Oncology, Sweden commented:

"It was inspiring to see the breadth of experience Dr. Boostrom has gathered in the U.S. The open discussion allowed us to compare approaches across different regions, and we left with several practical takeaways that will help us position TSE as a complement to currently available therapies and advance oncology animal care in our clinics."

Leadership Perspective

Mohan Frick, CEO of Scandinavian ChemoTech AB, concluded:

“The success of this session reflects the growing global community of veterinary oncologists committed to advancing cancer care for companion animals. By facilitating best practice exchanges between experienced users like Dr. Boostrom and large European veterinary account leading specialists, we are not only strengthening the adoption of TSE but also ensuring continuous improvement in outcomes. This collaborative spirit is exactly what drives our mission forward.”

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.